In summary, these data suggest that nevirapine has inhibitory effects in human dedifferentiated thyroid cancer by targeting the IL‐6/STAT3 signaling pathway, and our findings demonstrate that nevirapine may be useful as a therapy against human thyroid cancer. Here, STAT3 is linked to thyroid cancer.